---
title: "CSPC PHARMA  Receives USD15 million Development Milestone Payment for CRB-701"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306095007.md"
description: "CSPC PHARMA +0.315 (+3.945%) Short selling $335.37M; Ratio 31.537% announced that its subsidiary CStone Pharmaceuticals received a USD15 million development milestone payment from Corbus Pharmaceuticals related to CRB-701 (SYS 6002).To date, CStone Pharmaceuticals has cumulatively received upfront and development milestone payments totaling USD32.5 million from Corbus Pharmaceuticals under the agreement.The achievement of this milestone marks the steady progress of the relevant R&D work under the agreement as planned. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)"
datetime: "2026-11-19T09:31:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306095007.md)
  - [en](https://longbridge.com/en/news/306095007.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306095007.md)
generator: "portal-rs"
---

# CSPC PHARMA  Receives USD15 million Development Milestone Payment for CRB-701

CSPC PHARMA (01093.HK) +0.315 (+3.945%) Short selling $335.37M; Ratio 31.537% announced that its subsidiary CStone Pharmaceuticals received a USD15 million development milestone payment from Corbus Pharmaceuticals related to CRB-701 (SYS 6002).

To date, CStone Pharmaceuticals has cumulatively received upfront and development milestone payments totaling USD32.5 million from Corbus Pharmaceuticals under the agreement.

The achievement of this milestone marks the steady progress of the relevant R&D work under the agreement as planned. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)
- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [CSPC Pharmaceutical Starts Phase II Trial of SYH2072 for Hypertension in China](https://longbridge.com/en/news/304096545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**